Adverse reactions associated with antiretroviral regimens in adult patients of a university teaching hospital HIV program in Zaria, Northern Nigeria: An observational cohort study

Journal of Antivirals and Antiretrovirals

Volumn 4, Issue 1, 2012, Pages 006-013

  Reginald, Obiako O ^a   Haruna, Muktar M ^a   Sani, Garko B ^a   Eric, Tobi Ajayi ^a   Adebola, Olayinka T ^a   Mathew, Iyanda ^a   Chigozie, Irohibe ^a   Bilkisu, Umar ^a   Ibrahim, Abdu Aguye ^a  

^a AHMADU BELLO UNIVERSITY   (Nigeria)

Author keywords

Adverse drug reactions; Antiretroviral regimens; HAART; Nigeria; Pharmacovigilance; Zaria

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG SURVEILLANCE PROGRAM; FEMALE; FINGER NAIL; HEADACHE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPERSALIVATION; INSOMNIA; JAUNDICE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA AND VOMITING; NEURITIS; NIGERIA; OBSERVATIONAL STUDY; RASH; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TEACHING HOSPITAL; UNPLEASANT DREAM;

EID: 84857566131     PISSN: None     EISSN: 19485964     Source Type: Journal    
DOI: 10.4172/jaa.1000039     Document Type: Article

References (42)

1. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, et al. (2008) Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 168: 86-93.
2. Coney DM, Kim HW, Salazar R, Illescas R, Villena J, et al. (2007) Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr 44: 451-455.
3. Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, et al. (2007) Clinical toxicity of highly active antiretroviral therapy in home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 44: 456-462.
4. Castelnuovo B, John L, Lutwama F, Roland A, Spacek LA, et al. (2009) Three year outcome data of second-line antiretroviral therapy in Ugandan adults: Good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic) 8: 52-59.
5. Castelnuovo B, Kiragga A, Kamya MR, Manabe Y (2010) Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr 56: 59-63.
6. Laurent C, Bourgeois A, Mpoudi-Ngolé E, Ciaffi L, Kouanfack C, et al. (2008) Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses 24: 393-399.
7. First-line adult antiretroviral regimen recommendations (2009) In: APIN Plus/ Harvard PEPFAR adult antiretroviral treatment protocol 18.
8. O'Brien ME, Clark R, Besh L, Myers L, Kissinger P (2003) Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 34: 407-414.
9. Dragovic G, Jevtovic D (2003) Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy. Antivir Chem Chemother 14: 281-284.
10. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, et al. (2001) Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infec Dis 33: 1931-1937.
11. Pujades-Rodriguez M, Humblet P, Balkan S (2008) Reported severe toxicity during 36 months of ART: a multicentric longitudinal study in nineteen African and Asian HIV/AIDS programmes. Presented at: XV International Conference on AIDS and STIs in Africa Dakar, Uttarakhand.
12. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, et al. (2006) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 7: 487-503.
13. United States Department of Health and Human Services (2006) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.
14. World Health Organization (2011) Addendum to 2006 WHO guidelines on antiretroviral treatment therapy for HIV infection in adults and adolescents.
15. World Health Organization (2007) National Guideline for HIV and AIDS treatment and care in adolescents and adults. Federal Ministry of Health, Abuja- Nigeria.
16. Enrollment Procedures (2009) APINPlus/HarvardPEPFAR. In: Adult Antiretroviral treatment protocol 8-14.
17. Stone VE, Hogan JW, Schuman P, Rompalo AM, Howard AA, et al. (2001) Antiretroviral regimen complexity, self-reported adherence, and HIV patient's understanding of their regimens. J Acquir Immune Deficit Syndr 28: 124-131.
18. Edwards R, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356: 1255-1259.
19. The National Coordinator, National Pharmacovigilance (Drug Safety onitoring) Centre (NPC), National Agency for Food and Drug Administration and Control, (NAFDAC), Plot 2032 Olusegun Obasanjo way, Wuse Zone 7, Abuja.
20. APIN PLUS/HarvardPEPFAR ADULT PRESCRIPTION PAD (2009) In: Adult Antiretroviral treatment protocol 81-83.
21. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, et al. (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245.
22. Laurent C, Kouanfack C, Koulla-Shiro S, Njoume M, Nkene YM, et al. (2007) Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine. AIDS 21: 768-771.
23. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, et al. (2004) Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: Open-label multicentre trial. Lancet 364: 29-34.
24. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. The Lancet 356: 1423-1430.
25. Side effects of anti-HIV medications- Skin rash (2005) AIDS info. The US Department of Health and Human Services' guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.
26. Bain BJ (1999) Pathogenesis and pathophysiology of anemia in HIV infection. Curr Opin Hematol 6: 89-93.
27. Ssali F, Stohr W, Munderi P, Reid A, Walker AS, et al. (2006) Prevalence, incidence and predictors of severe anemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 11: 6:741-749.
28. Rachlis A, Fanning MM (1993) Zidovudine toxicity. Clinical features and management. Drug Saf 8: 312-320.
29. Don PC, Fusco F, Fried P, Batterman A, Duncanson FP, et al. (1990) Nail Dyschromia Associated with Zidovudine. Brief Reports 2: 145-146.
30. Sharma B (2011) Anti-HIV-1 drug toxicity and management strategies. Neurobehavioural HIV Medicine 3: 27-40.
31. Boeseck C, Cooper DA (2008) Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS 3: 653-659.
32. Tosini W, Muller P, Prazuck T, Benabdelmoumen G, Peyrouse E, et al. (2010) Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS 24: 2375-2380.
33. Braga Neto MB, Aquiar CV, Maciel JG, Oliveira BM, Sevilleja JE, et al. (2010) Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. BMC Gastroenterol 10: 90.
34. Saez-Llorens X, Violari A, Ndiweni D, Yogev R, Cashat M, et al. (2008) Longterm safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects. Pediatrics 121: 827-835.
35. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, et al. (2005) Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 143: 714-721.
36. APIN PLUS/Harvard PEPFAR adult antiretroviral drug regimens (2009) Other considerations. In: Adult Antiretroviral treatment protocol 19.
37. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, et al. (2005) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19: 399-406.
38. The ART-LINC Collaboration of the International Database to Evaluate AIDS (LeDEA),
39. Keiser O, Anastos K, Schechter M, Balestre E, et al. (2008) Antiretroviral therapy in resource-limited settings 1996 to 2006: Patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 7: 870-879.
40. Potchoo Y, Tchamdja K, Balogou A, Pitche VP, Guissou IP, et al. (2010) Knowledge and adherence to antiretroviral therapy among adult people with HIV/AIDS treated in the health care centers of "Espoir Vie Togo" in Togo, West Africa. BMC Clin Pharmacol 10: 11.
41. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, et al. (2007) Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 21: 2483-2491.
42. Reginald OO, Mohammed MH, Olayinka AT, Sani GB, Tobi-Ajayi E, et al. (2011) Hematological and Metabolic Toxicities of Current Antiretroviral Regimens in Ahmadu Bello University Teaching Hospital Shika Zaria, Northern Nigeria. J AIDS Clinic Res S2: 002.